Crackdown On Anti-Cancer Drugs Making Unit For Not Following Norms

Hyderabad: A drug manufacturing unit involved in production of anti-cancer injections as well as antibiotics without following the prescribed norms — was busted by the officials of Drugs Control Administration (DCA) on Wednesday.

The production unit was found making anti-cancer drug cyclophosphamide injection illegally during the raid conducted on Indian Genomix Pvt. Ltd at Cherlapally.

The company was involved in manufacturing cytotoxic, anti-cancer drugs as well as antibiotic injections. Without following the good manufacturing practices (GMPs) guidelines, these two types of drugs were being made at the same facility posing a major risk of cross-contamination of medicines. The production unit was not following the norms and thereby posing a serious health risk, DCA DG V.B. Kamalasan Reddy stated in a press statement on Wednesday.

The cytotoxic anti-cancer drug ‘cyclophosphamide injection’ alters the genetic material (DNA and RNA) of the cells and hence checks the growth or replication of cancer cells. It is used in providing chemotherapy to cancer patients and can cause severe side-effects, Kamalasan Reddy added.

The cytotoxic anti-cancer drugs should be manufactured at a separate, dedicated and self-contained production facility and as per the good manufacturing practices (GMPs) guidelines, so as to ensure a clear-cut separation of cytotoxic substances from other general drugs; otherwise ‘cross-contamination’ of general drugs with ‘cytotoxic anti-cancer drugs’ might lead to serious health consequences in a patient who is not suffering from cancer, he said.

A dedicated facility for handling cytotoxic drugs is crucial and Indian Genomix Pvt. Ltd. located at IDA Cherlapally was not following the norms while producing the anti-cancer drug. The drug manufacturing unit did have the requisite license for making anti-cancer drugs. The company was involved in manufacturing antibiotic injections, together with anti-cancer drugs posing a serious medical hazard, said the DG.

Related Posts

  • Pharma
  • May 16, 2025
  • 100 views
Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

US President Donald Trump’s move to slash prescription drug prices by tying them to rates in countries such as the UK and Germany may rattle multinational pharmaceutical giants, but it…

  • Pharma
  • May 16, 2025
  • 97 views
Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

Emcutix Biopharmaceuticals Ltd in partnership with Canada-based Mantra Pharma Inc—both subsidiaries of Emcure Pharmaceuticals Ltd—has launched Ureaderm 10% and 20%, a new range of urea-based moisturizers designed to address severe dryness…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

DCA seizes syrup stocks over misleading fever cure claim

DCA seizes syrup stocks over misleading fever cure claim

Mankind Pharma Faces Rs 341.86 Cr Tax Demand

Mankind Pharma Faces Rs 341.86 Cr Tax Demand

Piramal Pharma stock falls 5% after Q4 results; check key numbers here

Piramal Pharma stock falls 5% after Q4 results; check key numbers here

Biolumpivaxin: Bharat Biotech launches new vaccine against lumpy skin disease

Biolumpivaxin: Bharat Biotech launches new vaccine against lumpy skin disease